Home Cart Sign in  
Chemical Structure| 286930-03-8 Chemical Structure| 286930-03-8

Structure of Fesoterodine fumarate
CAS No.: 286930-03-8

Chemical Structure| 286930-03-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

(R)-Fesoterodine fumarate is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist.

Synonyms: SPM 907; SMP 8272; Fesoterodine (fumarate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fesoterodine fumarate

CAS No. :286930-03-8
Formula : C30H41NO7
M.W : 527.65
SMILES Code : O=C(O)/C=C/C(O)=O.CC(C)C(OC1=CC=C(CO)C=C1[C@@H](C2=CC=CC=C2)CCN(C(C)C)C(C)C)=O
Synonyms :
SPM 907; SMP 8272; Fesoterodine (fumarate)
MDL No. :MFCD12756004

Safety of Fesoterodine fumarate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01302054 Urinary Bladder, Overactive Phase 4 Completed - -
NCT01557244 Urinary Bladder, Neurogenic Phase 3 Recruiting November 13, 2019 -
NCT01302067 Overactive Bladder Phase 4 Completed - -
NCT01786967 - Completed - -
NCT01302067 - Completed - -
NCT00914667 Urinary Bladder, Overactive Phase 1 Completed - United States, Connecticut ... More >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 Less <<
NCT01786967 Urge Urinary Incontinence Phase 3 Completed - United States, North Carolina ... More >> UNC-Chapel Hill, Dept of Ob/Gyn Chapel Hill, North Carolina, United States, 27599 Less <<
NCT01302054 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.48mL

1.90mL

0.95mL

18.95mL

3.79mL

1.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories